Knowra Montelukast Montelukast Montelukast is an oral leukotriene receptor antagonist that blocks cysteinyl leukotriene signaling to help prevent asthma symptoms and relieve allergic rhinitis.
Cysteinyl leukotriene receptor 1 : A G protein-coupled receptor activated by cysteinyl leukotrienes, especially leukotriene D4. Montelukast chiefly works by blocking this receptor on airway and other cells.
Asthma : A chronic respiratory disease marked by variable airway narrowing, inflammation, and episodes of breathing difficulty. Montelukast is used for long-term control and prevention of asthma symptoms.
Montelukast boxed warning : The U.S. Food and Drug Administration's strongest warning about serious neuropsychiatric events reported with montelukast. This warning advises weighing risks and benefits, especially when treating allergic rhinitis.
Leukotriene receptor antagonist : A medicine that blocks receptors activated by leukotrienes, reducing selected inflammatory effects. Montelukast is a member of this drug class.
Leukotrienes : Inflammatory lipid mediators derived from arachidonic acid that influence airway tone, vascular permeability, and immune responses. Montelukast interrupts effects of the cysteinyl leukotriene family.
Allergic rhinitis : Inflammation of the nasal lining triggered by allergens, commonly causing sneezing, congestion, and itching. Montelukast can relieve symptoms, though other treatments are often preferred.
Neuropsychiatric adverse effects : Unwanted changes in mood, behavior, thinking, or sleep associated with a medication or illness. Reports of these effects prompted heightened precautions for montelukast.
Oral administration : Delivery of a medicine by swallowing it for absorption through the gastrointestinal tract. Montelukast is taken by mouth, unlike inhaled asthma controllers.
Arachidonic acid : A polyunsaturated fatty acid in cell membranes that serves as a precursor for several signaling molecules. Leukotrienes targeted by montelukast are produced from this fatty acid.
Exercise-induced bronchoconstriction : Temporary narrowing of the airways during or after physical exertion. Montelukast is approved to help prevent this asthma-related response.
Show all 22